Almost exactly one year ago, with holiday travel on my mind, I wrote about a medication that could potentially help with jet lag. Now, as reported by Shots, the FDA declined to approve Nuvigil as a remedy for the condition:
...The regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' "excessive sleepiness" outweighed its risks. In March, the FDA turned down Cephalon's jet-lag application and questioned how good the data supporting it really were. Cephalon soldiered on, giving FDA more data.
But today the company said its response fell short. In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:
[T]he company believes that further communications with the FDA will not result in an approval of this application. As a result, the company is no longer pursuing this indication.
From December 20 to January 3, Scope will be on a limited holiday publishing schedule. During that time, you may also notice a delay in comment moderation. We will return to our regular schedule on January 3.